National Health Investorsの空売り状況は、投資家がNational Health Investorsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

National Health Investors (NYSE:NHI) 株価情報, 空売り情報

National Health Investors

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.

National Health Investors, Inc. Common Stock

National Health Investors Inc

NewHold Investment Corp III - Class A Ordinary shares

NewHold Investment Corp III

NantHealth Inc

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments.
It is set to report its Q1 2025 earnings on May 5. Wall Street analysts expect the company to post EPS of $1.13, up from $1.12 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $85.13 million, up from $81.51 million a year earlier.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">If You Bought National Health Investors Stock 10 Years Ago</h2>
The company's stock traded at approximately $70.66 per share 10 years ago. If you had invested $10,000, you could have bought roughly 142 shares. Currently, shares trade at $70.20, meaning your investment's value could have declined to $9,935 from stock price depreciation. However, National Health Investors also paid dividends during these 10 years.&nbsp;
National Health Investors' dividend yield is currently 5.04%. Over the last 10 years, it has paid about $38.91 in dividends per share, which means you could have made $5,507 from dividends alone.&nbsp;
Summing up $9,935 and $5,507, we end up with the final value of your investment, which is $15,442. This is how much you could have made if you had invested $10,000 in National Health Investors stock 10 years ago. This means a total return of 54.42%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 193.10%.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
National Health Investors has a consensus rating of "Hold" and a price target of $68 based on the ratings of 14 analysts. The price target implies a more than 3% potential downside from the current stock price.
On Feb. 25, the company announced its Q4 2024 earnings, posting FFO of $1.12, compared to the consensus of $1.11, and revenues of $85.75 million, compared to the consensus of $82.67 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43957300/national-health-investors-q4-2024-ffo-1-12-beats-1-11-estimate-sales-85-75m-beat-82-67m-estimate">Benzinga.</a>
&#8220;The fourth quarter results exceeded our internal expectations as fundamentals remain strong throughout the portfolio with continued improvement in EBITDARM coverage trends, year-over-year cash rental income growth of 8.6%, SHOP NOI growth of 12.5%, and positive contributions from acquisitions completed during the year,&#8221; said CEO Eric Mendelsohn.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The company provided its full-year 2025 guidance, expecting normalized FFO attributable to common stockholders in the range of $214.7 million to $218.1 million.
Given the expected downside potential, growth-focused investors may not find National Health Investors stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 5.04%.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44659667/why-manpowergroup-regions-financial-and-nexstar-mediaare-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments.
It is set to report its Q1 2025 earnings on May 5. Wall Street analysts expect the company to post EPS of $1.13, up from $1.12 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $85.13 million, up from $81.51 million a year earlier.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">If You Bought National Health Investors Stock 10 Years Ago</h2>
The company's stock traded at approximately $70.66 per share 10 years ago. If you had invested $10,000, you could have bought roughly 142 shares. Currently, shares trade at $70.20, meaning your investment's value could have declined to $9,935 from stock price depreciation. However, National Health Investors also paid dividends during these 10 years.&nbsp;
National Health Investors' dividend yield is currently 5.04%. Over the last 10 years, it has paid about $38.91 in dividends per share, which means you could have made $5,507 from dividends alone.&nbsp;
Summing up $9,935 and $5,507, we end up with the final value of your investment, which is $15,442. This is how much you could have made if you had invested $10,000 in National Health Investors stock 10 years ago. This means a total return of 54.42%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 193.10%.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
National Health Investors has a consensus rating of "Hold" and a price target of $68 based on the ratings of 14 analysts. The price target implies a more than 3% potential downside from the current stock price.
On Feb. 25, the company announced its Q4 2024 earnings, posting FFO of $1.12, compared to the consensus of $1.11, and revenues of $85.75 million, compared to the consensus of $82.67 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43957300/national-health-investors-q4-2024-ffo-1-12-beats-1-11-estimate-sales-85-75m-beat-82-67m-estimate">Benzinga.</a>
&#8220;The fourth quarter results exceeded our internal expectations as fundamentals remain strong throughout the portfolio with continued improvement in EBITDARM coverage trends, year-over-year cash rental income growth of 8.6%, SHOP NOI growth of 12.5%, and positive contributions from acquisitions completed during the year,&#8221; said CEO Eric Mendelsohn.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The company provided its full-year 2025 guidance, expecting normalized FFO attributable to common stockholders in the range of $214.7 million to $218.1 million.
Given the expected downside potential, growth-focused investors may not find National Health Investors stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 5.04%.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44659667/why-manpowergroup-regions-financial-and-nexstar-mediaare-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

If You Invested $10K In National Health Investors Stock 10 Years Ago, How Much Would You Have Now?

News

National Health Investors Acquires $63.5 Million Memory Care Portfolio In Nebraska, Expanding Senior Living Investments

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $70 to $76.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $76

Wedbush analyst Richard Anderson reiterates National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Outperform and maintains $88 price target.

Reiteration

Wedbush Reiterates Outperform on National Health Investors, Maintains $88 Price Target

Juniper Village at Paramus, a community with 98 assisted living units and 22 memory care units, has been operated by Juniper Communities, an operator of 28 senior housing communities across five states, since February 2021.&nbsp;

Health Care

General

National Health Investors Invested $46.3M To Acquire Juniper Village At Paramus, A Senior Housing Community In Bergen County, NJ

On March 5, it was revealed in an SEC filing that ROBERT MCCABE JR, Director at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760225008392//Archives/edgar/data/877860/000112760225008392/0001127602-25-008392-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that JR, Director at National Health Investors, a company in the Real Estate sector, just exercised stock options worth 0 shares of NHI stock with an exercise price of $0.0.
The Thursday morning update indicates National Health Investors shares down by 1.66%, currently priced at $72.18. At this value, JR's 0 shares are worth $0.
<h3>Discovering National Health Investors: A Closer Look</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>National Health Investors's Financial Performance</h3>
Positive Revenue Trend: Examining National Health Investors's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.92% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 96.68%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): National Health Investors's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.96.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.84.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 23.45 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 9.66 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 16.94 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Decision Unfolding At National Health Investors: ROBERT MCCABE JR Exercises Options, Resulting In $0

A significant insider transaction involving the exercise of company stock options was reported on March 5, by CARLTON KEVIN PASCOE, Chief Investment Officer at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>), as per the latest SEC filing.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760225008409//Archives/edgar/data/877860/000112760225008409/0001127602-25-008409-index.htm">U.S. Securities and Exchange Commission</a>, PASCOE, Chief Investment Officer at National Health Investors, exercised stock options for 0 shares of NHI. The transaction value amounted to $0.
National Health Investors shares are trading down 1.66% at $72.18 at the time of this writing on Thursday morning. Since the current price is $72.18, this makes PASCOE's 0 shares worth $0.
<h3>Unveiling the Story Behind National Health Investors</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Financial Milestones: National Health Investors's Journey</h3>
Revenue Growth: National Health Investors's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.92%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 96.68%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): National Health Investors's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.96.
</li>
</ul>
Debt Management: National Health Investors's debt-to-equity ratio is below the industry average. With a ratio of 0.84, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 23.45 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.66, National Health Investors's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 16.94, National Health Investors's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Engaging In Insider Activity, CARLTON KEVIN PASCOE At National Health Investors Exercises Options Worth $0

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.11 by 0.9 percent. This is a 2.75 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $85.75 million which beat the analyst consensus estimate of $82.67 million by 3.72 percent. This is a 7.91 percent increase over sales of $79.47 million the same period last year.

Earnings

Earnings Beats

National Health Investors Q4 2024 FFO $1.12 Beats $1.11 Estimate, Sales $85.75M Beat $82.67M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and lowers the price target from $78 to $72.

Truist Securities Maintains Hold on National Health Investors, Lowers Price Target to $72

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">National Health Investors Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>)</h3>
<ul>
<li>On Nov. 5, the company reported quarterly sales of $82.94 million which beat the analyst consensus estimate of $79.21 million. Eric Mendelsohn, NHI President and CEO, stated, &#8220;Fundamentals remain strong across much of the portfolio with occupancy and EBITDARM coverage improving sequentially from the second quarter across our major asset classes.&#8221; The company's stock fell around 8% over the past month and has a <a href="https://www.benzinga.com/quote/NHI">52-week low of $51.59</a>.</li>
<li>RSI Value: 29.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>NHI Price Action: Shares of National Health Investors fell 1.6% to close at $74.35 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1">latest NHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74.png" alt="" class="wp-image-684847" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74-768x713.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Site Centers Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>)&nbsp;&nbsp;</h3>
<ul>
<li>On Nov. 4, the company said third quarter net income attributable to common shareholders was $320.2 million, or $6.07 per diluted share. &#8220;SITE Centers completed the planned spin-off of Curbline Properties on October 1, unlocking a unique and scalable opportunity focused on convenience real estate and providing investors with two distinct business plans,&#8221; commented David R. Lukes, President and Chief Executive Officer. The company's stock fell around 5% over the past month and <a href="https://www.benzinga.com/quote/DOW">has a 52-week low</a> of $10.19.</li>
<li>RSI Value: 27.10</li>
<li>SITC Price Action: Shares of Site Centers gained 0.6% to close at $15.43 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1">trend in SITC stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="858" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69.png" alt="" class="wp-image-684747" style="width:698px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69-768x727.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">Gladstone Land Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAND#NASDAQ">LAND</a>)</h3>
<ul>
<li>On Nov. 15, Gladstone Land announced the retirement of COO Terry Lee Brubaker. President and Chief Executive Officer, David Gladstone, stated, &#8220;Terry has been an integral part of the Gladstone family since inception. His tenure at Gladstone has been marked by remarkable growth and steadfast dedication. Terry&#8217;s commitment to our funds and our shareholders will be missed.&#8221; The company's stock fell around 12% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/LAND">low of $4.68</a>.</li>
<li>RSI Value: 24.17</li>
<li>LAND Price Action: Shares of Braskem fell 5.8% to close at $4.82 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1">breakout in LAND shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="663" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70.png" alt="" class="wp-image-684748" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70-300x221.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70-768x565.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42389952/top-3-materials-stocks-that-may-rocket-higher-in-december">Top 3 Materials Stocks That May Rocket Higher In December</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

LAND

SITC

Top 3 Real Estate Stocks Which Could Rescue Your Portfolio In Q4

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

Guidance

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.08 by 4.63 percent. This is a 4.63 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $82.94 million which beat the analyst consensus estimate of $79.21 million by 4.72 percent. This is a 3.54 percent increase over sales of $80.11 million the same period last year.

Earnings Misses

National Health Investors Q3 FFO $1.03 Misses $1.08 Estimate, Sales $82.94M Beat $79.21M Estimate

National Health Investors (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhi#NYSE">NHI</a>) has been on a downward spiral lately with significant selling pressure. After declining 10.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.
<h2>How to Determine if a Stock is Oversold</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Why a Trend Reversal is Due for NHI</h2>
The heavy selling of NHI shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 28.46. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.
<img alt="3-month RSI Chart for NHI" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/544/NHI_RCI14.jpeg" style="height:auto; width:100%" title="" />
This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering NHI in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 0.1% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, NHI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2350593/here-s-why-national-health-investors-nhi-is-poised-for-a-turnaround-after-losing-10-18-in-4-weeks?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2350593">To read this article on Zacks.com click here.</a>

Mid Cap

Technicals

Here's Why National Health Investors is Poised for a Turnaround After Losing -10.18% in 4 Weeks

Welltower Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/well#NYSE">WELL</a>) owns a diversified portfolio of healthcare real estate assets in the key markets of the United States, Canada and the U.K. The favorable senior housing industry, capital-recycling efforts and a healthy balance sheet are likely to continue aiding the company to ride the growth curve.
This Toledo, OH-based healthcare real estate investment trust (REIT) has gained 36.8% in the past six months compared with the industry&#39;s 13.8% growth.
Analysts seem bullish on this Zacks Rank #2 (Buy) company. The Zacks Consensus Estimate for WELL&#39;s 2024 FFO per share has moved marginally northward over the past two months to $4.19.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/54/80607.jpg?v=60877358" />
Image Source: Zacks Investment Research
<h2>Factors That Make Welltower a Solid Pick</h2>
Favorable SHO Portfolio Dynamics: Given an aging population and an expected rise in senior citizens&#39; healthcare expenditure, Welltower&#39;s seniors&#39; housing operating portfolio is well-poised to capitalize on this positive trend. Muted new supply has also been a tailwind for this industry.
With a supply-demand imbalance, the portfolio is expected to experience sustained occupancy growth in 2024 and the coming years. Capitalizing on these positive aspects, Welltower&#39;s SHO portfolio is well-prepared for compelling multiyear revenue growth. In 2024, management anticipates the same-store SHO NOI to grow within 19-23%, driven by favorable results and expectations for continued strength in the second half of 2024.
Favorable OM Visit Trend: There has been a favorable outpatient visits trend compared with in-patient admissions. Banking on this, the company is optimizing its outpatient medical (OM) portfolio, growing relationships with health system partners, and deploying capital in strategic acquisitions. From the beginning of 2024 through July 29, 2024, Welltower carried out pro-rata acquisitions and loan funding totaling $45.6 million for one OM property.
Given the favorable secular trends and growing need for value-based care, the company&#39;s efforts to strengthen its OM footprint will boost long-term growth.
Capital-Recycling Efforts: WELL&#39;s capital-recycling efforts to finance near-term investment and development opportunities highlight its prudent capital management practices and pave the way for long-term growth.
From the beginning of 2024 through July 29, 2024, the company completed pro-rata gross investments of $2.12 billion. This included $1.63 billion in acquisitions and loan funding and $492.7 million in development funding. During this period, pro rata property dispositions and loan payoffs totaled $685.5 million. As of June 30, 2024, eight SHO and one OM properties were classified as held for sale.
Balance Sheet &amp; Cash Flow Strength: Welltower maintains a healthy balance sheet position and has $8.7 billion of available liquidity as of July 26, 2024. The company enjoys investment-grade credit ratings of BBB+ and Baa1 from S&amp;P Global Ratings and Moody&#39;s, respectively, rendering it access to the debt market at favorable rates.
With a well-laddered debt maturity schedule and enough financial flexibility, Welltower is likely to meet its near-term obligations and fund its development pipeline.
WELL&#39;s current cash flow growth is projected at 20.65% compared with a decline of 4.03% estimated for the industry.
<h2>Other Stocks to Consider</h2>
Some other top-ranked stocks from the broader REIT sector are National Health Investors (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhi#NYSE">NHI</a>) and Alpine Income Property Trust (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pine#NYSE">PINE</a>), each carrying a Zacks Rank #2 at present.
The Zacks Consensus Estimate for National Health Investors&#39; 2024 FFO per share is pegged at $4.55, which suggests year-over-year growth of 5.1%.
The Zacks Consensus Estimate for Alpine&#39;s full-year FFO per share stands at $1.65, which indicates an increase of 12.2% from the year-ago period.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
<a href="https://www.zacks.com/stock/news/2347046/here-s-why-welltower-stock-is-an-apt-portfolio-pick-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347046">To read this article on Zacks.com click here.</a>

Large Cap

REIT

Small Cap

Management

Real Estate

PINE

WELL

Here's Why Welltower Stock is an Apt Portfolio Pick for Now

Wells Fargo analyst John Kilichowski assumes National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Equal-Weight rating and raises Price Target to $86.

Initiation

Wells Fargo Assumes National Health Investors at Equal-Weight, Raises Price Target to $86

B of A Securities analyst Joshua Dennerlein initiates coverage on National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Buy rating and announces Price Target of $92.

B of A Securities Initiates Coverage On National Health Investors with Buy Rating, Announces Price Target of $92

In a new SEC filing on September 5, it was revealed that WEBB, Board Member at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>), executed a significant exercise of company stock options.
What Happened: The latest Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760224023589//Archives/edgar/data/877860/000112760224023589/0001127602-24-023589-index.htm">U.S. Securities and Exchange Commission</a> uncovered WEBB, Board Member at National Health Investors, exercising stock options for 70,000 shares of NHI. The total transaction was valued at $1,585,550.
The Friday morning update indicates National Health Investors shares down by 0.0%, currently priced at $82.51. At this value, WEBB's 70,000 shares are worth $1,585,550.
<h3>All You Need to Know About National Health Investors</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Understanding the Numbers: National Health Investors's Finances</h3>
Revenue Growth: National Health Investors's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 9.11%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 96.7%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.81, National Health Investors showcases strong earnings per share.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.91, National Health Investors adopts a prudent financial strategy, indicating a balanced approach to debt management.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 28.06, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.99 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 18.63, National Health Investors presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ROBERT WEBB At National Health Investors Decides to Exercises Options Worth $1.59M

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $65 to $78.

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $78

On August 27, it was revealed in an SEC filing that James Jobe, Director at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760224023009//Archives/edgar/data/877860/000112760224023009/0001127602-24-023009-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Jobe, Director at National Health Investors in the Real Estate sector, exercised stock options for 45,000 shares of NHI stock. The exercise price of the options was $54.67 per share.
As of Wednesday morning, National Health Investors shares are up by 0.48%, with a current price of $81.07. This implies that Jobe's 45,000 shares have a value of $1,187,999.
<h3>Get to Know National Health Investors Better</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Financial Insights: National Health Investors</h3>
Revenue Growth: National Health Investors's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.11%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 96.7%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): National Health Investors's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.81.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.91.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 27.44, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.75 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 18.32, National Health Investors presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: James Jobe Exercises Options At National Health Investors For $1.19M

Dividends

Press Releases

NHI Announces First Quarter 2025 Dividend

NHI Issues Investor Update

NHI Announces $46.3 Million Senior Housing Investment

NHI Announces Appointment of Robert W. Chapin, Jr. to the Board of Directors

NHI Announces $63.5 Million Senior Housing Investment

National Health Investors, Inc. Highlights Steps Taken to Deliver Stockholder Value

Land & Buildings Sends Letter to National Health Investors Stockholders and Files Definitive Proxy Materials Detailing Urgent Need for Boardroom Change

NHI Announces First Quarter 2025 Earnings Release and Conference Call Dates

NHI Mails Letter to Stockholders Highlighting Superior Shareholder Returns and Refreshed Board

NHI Reschedules First Quarter 2025 Earnings Conference Call and Webcast Starting Time

Comments

National Health Investors

空売り

National Health Investors (NYSE:NHI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル